Isogenica develops LlamdA® VHH, versatile antibodies for bi- and multi- specifics, ADCs, cell and gene therapies.
Single Domain Biotherapeutics
Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.
LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.
Meet our Team
Our experienced team learned their craft at Ablynx, Bicycle Therapeutics, Roche and other leading biopharma.